Optimization of competitively differentiated polymerase chain reaction in detection of HBV basal core promoter mutation

Xiao-Mou Peng, Lin Gu, Xue-Juan Chen, Jian-Guo Li, Yang-Su Huang, Zhi-Liang Gao

AIM: To improve competitively differentiated polymerase chain reaction (CD-PCR) in detection of HBV basal core promoter mutation.

METHODS: Recombinant plasmid of double point mutation A1762T/G1764A in basal core promoter of HBV constructed by site-directed mutagenesis was used as mutant control. To reveal the deficiency mechanism of CD-PCR, relationship between the circle number of PCR and the increased speed of products of each competitive primer was comparatively studied. Diversified amount of dNTPs and mutual primer of the competitive primers were tried to optimize CD-PCR. Optimized CD-PCR was evaluated by detecting A1762T/G1764A mutation in recombinant plasmids and clinical sera from patients with HBV infection.

RESULTS: The deficiency mechanism of CD-PCR was that the products of mismatched competitive primer grew fast when the amplification of matched primer entered into plateau stage, which led to decrease in or disappearance of the difference in the amount of their products. This phenomenon could be eliminated by reducing dNTPs to 10 μmol/L and mutual primer to about 100 nmol/L. Optimized CD-PCR could detect both mutant and wild strain independent of the amount of templates and the number of PCR cycles. Its detection limit was 10^2 copies/mL, about 50 copies/reaction. About 10% of mutant DNAs among wild type DNAs could be detected. A1762T/G1764A mutant was detected in 41.8% (51/122) of patients with HBV infection, but not detected in controls with negative HBsAg.

CONCLUSION: Optimized CD-PCR can detect mutation independent of the amount of initial templates and the number of PCR cycles.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

INTRODUCTION

Hepatitis B virus (HBV) is a significant cause of life-threatening liver diseases, such as fulminating hepatitis, liver cirrhosis and hepatocellular carcinoma[1-3]. HBV point mutations, including precore stop mutation G1896A, immune escape mutations K141E, P142S, D144E and G145R, basal core promoter double point mutation A1762T/G1764A and lamivudine-resistant mutation M552I or M552V, are very common and have important implications in the pathogenesis, treatment and prevention of chronic HBV infection[4-9]. Thus, to demonstrate these mutants in time is very important in clinical practice.

Many methods are used in detection of point mutations, especially in laboratory researches. Most methods are based on polymerase chain reaction (PCR). To analyze PCR products using direct sequencing is gold standard, but cannot be used in routine clinical examination. Thus, new methods are still emerging, including fluorometric real time PCR methods[10-12] and other methods to analyze PCR products using restriction fragment length polymorphism and enzyme linked mini-sequence assay (SMITEST)[13]. Fluorometric real time PCR is based on the small differences in hybridization melting curve kinetics of the probes and needs expensive apparatus[10]. To analyze PCR products usually needs much additional manipulation. PCR with elaborately designed primers, such as allele specific-PCR (AS-PCR) and sequence specific-PCR or amplification refractory mutation system[14,15], is usually simple and rapid. However, its specificity is influenced by the amount of initial templates[16]. Unfortunately, the amount of HBV DNA in sera of patients with HBV infection varies greatly and is uncontrollable.

For these reasons, a novel method of competitively differentiated PCR (CD-PCR) was developed in our laboratory, which can rapidly and effectively demonstrate HBV precore mutation G1896A. CD-PCR was established based on AS-PCR. It employs competitive primers and a differentiation stage to minimize the adverse influence of the amount of initial templates and to stop the cross amplification between...
wild and mutant products in subsequent cycles. Theoretically, the difference in PCR products between two competitive primers is independent of the amount of initial templates. However, CD-PCR only has an enlarged distinguishable range (10²-10⁸ copies/mL) as compared with AS-PCR, and clinical samples with high level of HBV DNA have to be diluted before examination. In this study, the deficiency of CD-PCR was investigated and its main components were optimized based on analysis of the PCR products using enzyme immunoassay (EIA).

**MATERIALS AND METHODS**

**Reagents**

Recombinant plasmid pTZ19U-HBV containing double copies of HBV DNA (adv) was a present from Professor Zhi-Min Huang, Zhongshan University. T4 DNA ligase and pfu DNA polymerase were purchased from Promega Company (USA). DNA gel extraction, plasmid isolation and serum DNA extraction kits were purchased from Omega Company (USA). Anti-digoxigenin and anti-fluorescein labeled with horseradish peroxidase were purchased from Roche Company (USA).

**Oligonucleotides**

Primers and probes shown in Table 1 were designed with the software Omega 2 and synthesized in Bioasia Biological Engineering Company (Shanghai, China). The sequence of BCP-c1 was in concordance with the A1762T/G1764A mutant control. BCP1-M and BCP1-W were competitive primers for mutant and wild strain, respectively. PCA was the mutual anti-sense primer of two competitive primers.

**Serum samples and DNA extraction**

One hundred serum samples with HBsAg (+), anti-HBe (+) and anti-HBc (+) and 60 serum samples with HBsAg (+), HBsAg (+) and anti-HBc (+) and 40 serum samples without HBV serum markers were collected. The serum markers were demonstrated by enzyme-linked immunosorbent assay. HBV DNA level in sera was extracted using Omega kits, recovered in 50 μL PCR reaction. The reaction mixture contained 10 mmol/L Tris-HCl, pH 8.5, 50 mmol/L KCl, 1.5 mmol/L MgCl₂, optimized amount of dNTPs, 2U pfu DNA polymerase, optimized amount of competitive primers (BCP-M, BCP-W), PCA and 5 μL plasmid or extracted DNA. The cycling conditions were as follows: two cycles (first set) at 94 °C for 60 s, at 53 °C for 120 s and at 72 °C for 120 s, followed by 38 cycles (second set) at 94 °C for 30 s, at 65 °C for 30 s, and at 72 °C for 60 s. The PCR products were then hybridized with solidified biotin-labeled probe PCP in two different wells of microtiter plate. Color reaction was obtained after captured PCR products were reacted with horseradish peroxidase-labeled anti-DIG or anti-FITC. The optical absorption density (A value) was measured, and the ratio (A_m/A_w) of A values in two wells with horseradish peroxidase-labeled anti-DIG (A_m) or anti-FITC (A_w) was used as criteria for the result analysis. The amount and ratio of competitive primers were determined as A_m for mutant control and A_w for wild control were almost similar when 10² copies/mL of recombinant plasmids pHB-BCP2 and pTZ19U-HBV were used as mutant control and wild control, respectively.

**Construction of mutant control using site-directed mutagenesis**

To construct A1762T/G1764A mutant controls, pTZ19U-HBV was used as template, BCP-c1 and BCP-c2 were used as primers in PCR to obtain A1762T/G1764A mutant fragments. The mutant fragments were then cloned into plasmid pUC19 to generate recombinant plasmid pHB-BCP2. After the sequences were confirmed by DNA sequencing, the recombinant plasmid was used as mutant control in CD-PCR.

**Basic CD-PCR for detection of A1762T/G1764A mutant**

Principles of competitive primer design and CD-PCR for detection of HBV G1896A mutation were previously described. It was modified for detection of BCP mutation. Briefly, 25 μL PCR reaction was performed. The reaction mixture contained 10 mmol/L Tris-HCl, pH 8.5, 50 mmol/L KCl, 1.5 mmol/L MgCl₂, optimized amount of dNTPs, 2U pfu DNA polymerase, optimized amount of competitive primers (BCP-M, BCP-W), PCA and 5 μL plasmid or extracted DNA. The cycling conditions were as follows: two cycles (first set) at 94 °C for 60 s, at 53 °C for 120 s and at 72 °C for 120 s, followed by 38 cycles (second set) at 94 °C for 30 s, at 65 °C for 30 s, and at 72 °C for 60 s. The PCR products were then hybridized with solidified biotin-labeled probe PCP in two different wells of microtiter plate. Color reaction was obtained after captured PCR products were reacted with horseradish peroxidase-labeled anti-DIG or anti-FITC. The optical absorption density (A value) was measured, and the ratio (A_m/A_w) of A values in two wells with horseradish peroxidase-labeled anti-DIG (A_m) or anti-FITC (A_w) was used as criteria for the result analysis. The amount and ratio of competitive primers were determined as A_m for mutant control and A_w for wild control were almost similar when 10² copies/mL of recombinant plasmids pHB-BCP2 and pTZ19U-HBV were used as mutant control and wild control, respectively.

**Optimization of CD-PCR**

Two hundred, 50, 10 and 2 μmol/L of dNTPs and 500, 250, 100 and 50 mmol/L of primer PCA were comparatively studied. Two hundred microliters PCR reaction was performed with three parallel tubes. The products were analyzed at every five circles.

**DNA sequencing**

Fragments of HBV basal core promoter, precore and core from 10 samples (five mutants, and five wild strains of HBV according to CD-PCR) were analyzed by DNA sequencing. The products were analyzed at every five circles.

---

**Table 1 Primers and probe**

| Denomination | Sequences |
|--------------|-----------|
| PCSc         | 5'-CCCGAGTTCCACCCGGTAAACGGGCAATCAG3'-3' |
| PCAc         | 5'-CCCAAGTGCTGACAGTACGGTAGTGGACGAAATG3'-3' |
| BCP-c1       | 5'-CCGAGTTCCAGAGGGCGGAGAATAGTGATGGGTC-3' |
| BCP-c2       | 5'-AGAGCTGCGAGGATAGATGTCGACTGACGGGC-3' |
| BCP1-W       | 5'-FITC-CGGTAGGTGCGAGGAGGAGATTAGTTAAGG-3' |
| BCP1-M       | 5'-DIG-CGGTAGGTGCGAGGAGGAGATTAGTTAAGG-3' |
| PCA          | 5'-CTGGAGCAGCACTTAAAGGCGTCTCGATACAG-3' |
| PCP          | 5'-BIO-GACCGAAGGGAAGGAGACTGACAGGGGCAAA3'-3' |

The underlined nucleotides were loci of restriction endonucleases. The italic characters had no relationship with HBV genome.
RESULTS

Deficiency mechanism of CD-PCR
The deficiency mechanism of CD-PCR was that the products of mismatched competitive primer grew fast when the amplification of matched primer entered into plateau stage, which led to decrease in or disappearance of difference in the amount of their products (Figure 1).

Optimization of CD-PCR
When $10^7$ copies/mL of pHB-BCP2 were used as template, $A$ value of the products of matched competitive primer BCP-M ($A_m$) decreased, but the difference from the mismatched competitive primer BCP-W ($A_w$) was enlarged independent of the number of cycles as the concentration of dNTPs was gradually reduced (Figure 1). However, both $A_m$ and $A_w$ were greatly decreased at 2 $\mu$mol/L dNTPs, which was inconvenient for the method to be used further. The optimized concentration of dNTPs was about 10 $\mu$mol/L. Similar results were obtained when wild control pTZ19U-HBV was used as template. The concentration of primer PCA had an effect on CD-PCR similar to that of dNTPs and its optimized concentration was about 100 nmol/L.

Detection of BCP mutation in recombinant plasmid DNA using optimized CD-PCR
The CD-PCR results of 10-fold dilution ($10^1$-$10^{12}$/mL) of pHB-BCP2 and pTZ19U-HBV are shown in Figure 2. Both mutant and wild DNA could be detected using optimized CD-PCR independent of the amount of templates up to $10^{12}$ copies/mL, which was higher than the serum level of HBV DNA in patients with chronic HBV infection. Its limit of detection was $10^3$ copies/mL, about 50 copies/reaction.

Figure 1 Optimization of the concentration of dNTPs. $A$: optical absorption density, $A_m$ and $A_w$: $A$ values of wells with horseradish peroxidase-labeled anti-DIG ($A_m$) and anti-FITC ($A_w$), respectively, 1: 200 $\mu$mol/L of dNTPs, 2: 50 $\mu$mol/L of dNTPs, 3: 10 $\mu$mol/L of dNTPs, 4: 2 $\mu$mol/L of dNTPs.

Figure 2 Detection of BCP mutation in recombinant plasmid DNA using optimized CD-PCR. A: pHB-BCP2 as template, B: pTZ19U-HBV as template, C: $A_m/A_w$ ratio as criteria for the result analysis, D: detection BCP mutation among mixture of pHB-BCP2 and pTZ19U-HBV. $A$: optical absorption density, $A_m$ and $A_w$: $A$ values of wells with horseradish peroxidase-labeled anti-DIG ($A_m$) and anti-FITC ($A_w$), respectively, 0-100%: copy ratio of pHB-BCP2 with total recombinant plasmid DNA in mixture.
In order to demonstrate co-infections of mutant and wild HBV strains, the $A_m/A_n$ ratio was employed in this study (Figure 2). About 10% of mutant DNA among wild DNA could be detected. The preferable range for co-infection detection was $10^{-5}$ copies/mL.

**Detection of BCP mutant in clinical samples**

HBV DNA was positive in 122 of 200 serum samples for fluorescein quantitative PCR. The results of A1762T/G1764A mutant were shown in Table 2. A1762T/G1764A mutant was detected in 41.8% (51/122) of patients with HBV infection, but not detected in controls with negative HBsAg or in patients with negative HBV DNA. The DNA sequencing results of 10 selected samples were in concordance with those of CD-PCR.

| Cases(n) | HBV DNA n (%) | A1762T/G1764A n (%) |
|----------|---------------|---------------------|
| HBsAg(+)/HBeAg(+) | 60 | 60 (100.0) | 19 (31.7) |
| HBsAg(+)/HBeAg(-) | 100 | 62 (62.0) | 32 (51.6) |
| HBsAg(-)/HBeAg(-) | 40 | 0 | 0 |

\[\chi^2 = 29.90, \ P<0.01, \ \chi^2 = 4.99, \ P<0.05, \ \text{compared with the group of HBsAg (+)/HBeAg(+)}.\]

**DISCUSSION**

A simple and rapid method is urgently needed to meet massive patients and growing types of HBV mutants\cite{1-4,17,18-23,24-26}. CD-PCR may be one of those methods. However, clinical samples with high level of HBV DNA have to be diluted before examination, suggesting that CD-PCR still depends on the amount of initial templates.

The reason why CD-PCR is still dependent on the amount of initial templates is unclear. In our study, the products of mismatched competitive primer grew very fast when the amplification of matched primer came into the plateau stage, which led to the decrease in or disappearance of difference in the amount of their products, suggesting that the mismatched competitive primer is preponderant in competition in the later stage of PCR because of its dominance in number due to less consumption. To let the reaction stop before the formation of plateau like AS-PCR by reducing the cycles with the introduction of basic amplification previously\cite{27} or employing real time technique may be the right way to solve the problem. However, the former needs additional manipulation and increases the chance of contamination, and the later needs expensive apparatus. Optimized CD-PCR is independent of the number of cycles, suggesting optimized CD-PCR is sensitive since the templates at low level can be thoroughly amplified by increasing the number of cycles.

HBV A1762T/G1764A mutant is very common and usually accompanied with increase in HBV replication and decrease in HBeAg secretion, and may be related to liver deterioration\cite{28-30}, or does not affect HBV DNA level\cite{24}. This mutant occurs in patients with positive HBeAg, and may be predictive of seroconversion\cite{31}, or a favorable factor for interferon-induced anti-HBe seroconversion\cite{32}.

In conclusion, HBV A1762T/G1764A mutant may be responsible for HBeAg negative hepatitis, and should be detected routinely in clinical practice. Optimized CD-PCR can detect HBV mutation.

**REFERENCES**

1. Liaw YF. Therapy of chronic hepatitis B: current challenges and opportunities. *J Viral Hepat* 2002; 9: 393-399
2. Block TM, Mehta AS, Fimmel CJ, Jordan R. Molecular viral oncology of hepatocellular carcinoma. *Oncogene* 2003; 22: 5093-5107
3. Ganem D, Prince AM. Hepatitis B virus infection-natural history and clinical consequences. *N Engl J Med* 2004; 350: 1118-1129
4. Lin CL, Liao LY, Liu CJ, Chen PJ, Lai MY, Kao JH, Chen DS. Hepatitis B genotypes and precore/basal core promoter mutants in HBeAg-negative chronic hepatitis B. *J Gastroenterol Hepatol* 2002; 17: 283-287
5. He C, Nomura F, Itoga S, Isobe K, Nakai T. Prevalence of vaccine-induced escape mutants of hepatitis B virus in the adult population in China: a prospective study in 176 restaurant employees. *J Gastroenterol Hepatol* 2001; 16: 1373-1377
6. Jeantet D, Chemin I, Mandrand B, Zoulim F, Trepo C, Kay A. Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. *Hepatology* 2002; 35: 1215-1224
7. Kim KH, Lee KH, Chang HY, Ahn SH, Tong S, Yoon YJ, Seong BL, Kim SI, Han KH. Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. *J Med Virol* 2003; 71: 367-375
8. Poovorawan Y, Theamboonlers A, Chongsrisawat V, Sampavat S. Molecular analysis of the a determinant of HBsAg in children of HBeAg-positive mothers upon failure of postexposure prophylaxis. *Int J Infect Dis* 1998; 2: 216-220
9. Leung N. Viral breakthrough during lamivudine therapy for chronic hepatitis B. *Intervirology* 2003; 46: 344-349
10. Zhang M, Gong Y, Osowy C, Minuk GY. Rapid detection of hepatitis B virus mutations using real-time PCR and melting curve analysis. *Hepatology* 2002; 36: 723-728
11. Whalley SA, Brown D, Teo CG, Dashieko GM, Saunders NA. Monitoring the emergence of hepatitis B virus polymerase gene mutations in patients during lamivudine therapy using the LightCycler. *J Clin Microbiol* 2001; 39: 1456-1459
12. Pichkovskaia VA, Fevraleva IS, Ibragimova MM, Solov’eva TI, Drel’ PE, Sudarikov AB. Detection of YMDD mutations in hepatitis B virus DNA with the use of allele specific polymerase chain reaction. *Mal Gen Mikrobol Virusol* 2004: 27-29
13. Punia P, Cane F, Teo CG, Saunders N. Quantitation of hepatitis B lamivudine resistant mutants by real-time amplification refractory mutation system PCR. *J Hepatology* 2004; 40: 986-992
14. Matsuda M, Suzuki F, Suzuki Y, Tsubota A, Akuta N, Hosaka T, Someya T, Kobayashi M, Saito H, Arase Y, Satoh J, Takagi K, Kobayashi M, Ikeda K, Kumada H. Low rate of YMDD motif mutations in polymerase gene of hepatitis B virus in chronically infected patients not treated with lamivudine. *J Gastroenterol* 2004; 39: 34-40
15. Cameron-Wilson CL, Muir P, Ballard AL, Corden S, Boxall EH, Sablon E, Stuyver L. Evaluation of a line probe assay for identification of hepatitis B virus precore variants in serum from chronic hepatitis B carriers. *J Virol Methods* 2003; 114: 97-103
16. Jardi R, Buti M, Rodriguez-Frias F, Corrina M, Costa X, Pascual C, Esteban R, Guardia J. Rapid detection of lamivudine-resistant hepatitis B virus polymerase gene variants. *J Virol Methods* 1999; 83: 181-187
17. Hersberger M, Marti-Jaun J, Hanseler E, Speck RF. Rapid detection of the CCR2-V64I, CCR5-A59029G and SDF1-
G801A polymorphisms by tetra-primer PCR. Clin Biochem 2002; 35: 399-403

18 Yotsuyanagi H, Hino K, Tomita E, Toyoda J, Yasuda K, Iino S. Precore and core promoter mutations, hepatitis B virus DNA levels and progressive liver injury in chronic hepatitis B. J Hepatol 2002; 37: 355-363

19 Laras A, Koskinas J, Hadziyannis SJ. In vivo suppression of precore mRNA synthesis is associated with mutations in the hepatitis B virus core promoter. Virology 2002; 295: 86-96

20 Nakashima H, Furusyo N, Kubo N, Kashiwagi K, Etoh Y, Kashiwagi S, Hayashi J. Double point mutation in the core promoter region of hepatitis B virus (HBV) genotype C may be related to liver deterioration in patients with chronic HBV infection. J Gastroenterol Hepatol 2004; 19: 541-550

21 Mayerat C, Mantegani A, Spertini F, Frei PC. Mutations in the basal core promoter and precore/core gene of hepatitis B virus in patients with chronic active but not acute hepatitis B. Eur J Clin Microbiol Infect Dis 1999; 18: 871-878

22 Gerner P, Lausch E, Friedt M, Tratzmuller R, Spangenberg C, Wirth S. Hepatitis B virus core promoter mutations in children with multiple anti-HBe/HBeAg reactivations result in enhanced promoter activity. J Med Virol 1999; 59: 415-423

23 Kramvis A, Kow MC. The core promoter of hepatitis B virus. J Viral Hepat 1999; 6: 415-427

24 Gandhe SS, Chadha MS, Walimbe AM, Arankalle VA. Hepatitis B virus: prevalence of precore/core promoter mutants in different clinical categories of Indian patients. J Viral Hepat 2003; 10: 367-382

25 Yamaura T, Tanaka E, Matsumoto A, Rokuhara A, Orii K, Yoshizawa K, Miyakawa Y, Kiyosawa K. A case-control study for early prediction of hepatitis B e antigen seroconversion by hepatitis B virus DNA levels and mutations in the precore region and core promoter. J Med Virol 2003; 70: 545-552

26 Zampino R, Marrone A, Cirillo G, del Giudice EM, Utili R, Karayiannis P, Liang TJ, Ruggiero G. Sequential analysis of hepatitis B virus core promoter and precore regions in cancer survivor patients with chronic hepatitis B before, during and after interferon treatment. J Viral Hepat 2002; 9: 183-188